Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclam...Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclampsia. Methods: A total of 68 patients with severe preeclampsia who were treated in the hospital between October 2015 and August 2017 were chosen as the research subjects and divided into study group (n=34) and control group (n=34) by random number table method. Control group received magnesium sulfate therapy on the basis of conventional therapy, and study group received magnesium sulfate combined with labetalol therapy on the basis of conventional therapy. The differences in the expression of apoptosis and invasion molecules in placenta tissue as well as the levels of maternal endothelial function indexes were compared between the two groups. Results: Fas, Bax and Caspase-3 mRNA expression in the placenta tissues of study group were lower than those of control group whereas Bcl-2 mRNA expression was higher than that of control group;GPR30, LAMA4 and MEST mRNA expression in placenta tissues were lower than those of control group whereas CDKN1C mRNA expression was higher than that of control group;24 h before delivery, maternal serum ET-1 and vWF levels of study group were lower than those of control group whereas NO level was higher than that of control group (P<0.05). Conclusion: Magnesium sulfate combined with labetalol therapy can effectively inhibit the apoptosis of placental trophoblast cells and enhance their invasion ability, and also improve the maternal endothelial function in patients with severe preeclampsia.展开更多
文摘Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclampsia. Methods: A total of 68 patients with severe preeclampsia who were treated in the hospital between October 2015 and August 2017 were chosen as the research subjects and divided into study group (n=34) and control group (n=34) by random number table method. Control group received magnesium sulfate therapy on the basis of conventional therapy, and study group received magnesium sulfate combined with labetalol therapy on the basis of conventional therapy. The differences in the expression of apoptosis and invasion molecules in placenta tissue as well as the levels of maternal endothelial function indexes were compared between the two groups. Results: Fas, Bax and Caspase-3 mRNA expression in the placenta tissues of study group were lower than those of control group whereas Bcl-2 mRNA expression was higher than that of control group;GPR30, LAMA4 and MEST mRNA expression in placenta tissues were lower than those of control group whereas CDKN1C mRNA expression was higher than that of control group;24 h before delivery, maternal serum ET-1 and vWF levels of study group were lower than those of control group whereas NO level was higher than that of control group (P<0.05). Conclusion: Magnesium sulfate combined with labetalol therapy can effectively inhibit the apoptosis of placental trophoblast cells and enhance their invasion ability, and also improve the maternal endothelial function in patients with severe preeclampsia.
